Acarix AB (publ) (ACARIX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Acarix 2025 Q4 earnings call. Thanks for joining. As a reminder to shareholders as well as new shareholders, I want to give a little bit about what we do and how we do it. So we are Acarix with the CADS4 device, which is a high fidelity point of care diagnostic that helps to risk stratify patients with coronary artery disease symptoms like low to moderate chest pain or shortness of breath. We have quickly and easily risk-ratified patients with a 96.2% negative predictive value, which is on par or better than a number of more invasive testing that has procured for today. We have over 15 years of R&D, over 6,000 patients in clinical trials, 45 patents worldwide, and over 60,000 assessments to date. We are CE marked, FDA de novo cleared, and we're designated a class two medical device. We do have a CPT code in the United States for reimbursement, and we are headquartered in Sweden with our production in Copenhagen, and we have a focus on global sales. A little bit about our executive summary highlighting what we did in Q4 of 2025. We had revenue increase of 26%, which is pretty exciting to us, driven by 87% growth in the U.S. market, which is our most important market and our strategic focus. Our cash score deliveries grew 64% worldwide. Our financial performance and cost discipline was effective as we've procured ever since we've joined the organization. It remains strong from a gross margin standpoint at 83%, which continually reinforces our reoccurring revenue models. Our operating costs declined 23%, which provided a 27% improvement in our net loss. Our U.S. market momentum continually focused on reimbursement, which with another additional payer joining us. And we delivered four systems on consignment and 19 systems on a sales standp...